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INTRODUCTION
Urothelial carcinoma (UC) of the urinary bladder, the 
most common form of bladder cancer, remains the fourth 
most common malignancy in the United States, and ninth 
worldwide [1-3]. Among genitourinary malignancies, it trails 
only prostate cancer in incidence and mortality [1,4]. Of 
patients diagnosed with UC, 70% are nonmuscle invasive 
(NMIBC) and 30% are muscle invasive bladder cancer (MIBC) 
at the time of diagnosis [5]. While management of NMIBC 
requires regular surveillance, repeated transurethral 
resections (TURs), and use of intravesical agents, it is the 
subset of  patients diagnosed with MIBC or those who 
progress to MIBC that drive the mortality of this disease. 
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The incidence of urothelial carcinoma of the urinary bladder (bladder cancer) remains high. While other solid organ malignan-
cies have seen significant improvement in morbidity and mortality, there has been little change in bladder cancer mortality in the 
past few decades. The mortality is mainly driven by muscle invasive bladder cancer, but the cancer burden remains high even in 
nonmuscle invasive bladder cancer due to high recurrence rates and risk of progression. While apoptosis deregulation has long 
been an established pathway for cancer progression, nonapoptotic pathways have gained prominence of late. Recent research in 
the role of autophagy in other malignancies, including its role in treatment resistance, has led to greater interest in the role of au-
tophagy in bladder cancer. Herein, we summarize the literature regarding the role of autophagy in bladder cancer progression and 
treatment resistance. We address it by systematically reviewing treatment modalities for nonmuscle invasive and muscle invasive 
bladder cancer.
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The oft-cited 50% overall survival at 5 years for MIBC 
has remained relatively unchanged in 20 years. While 
management of other cancers has progressed rapidly, the 
management of bladder cancer remains relatively stagnant 
[6,7]. The one major change in management in that time 
period was the introduction of neoadjuvant platinum-based 
chemotherapy (NAC) for patients with nonmetastatic MIBC 
prior to undergoing radical cystectomy. Despite the 7% 
survival benefit demonstrated by NAC, the overall mortality 
of  bladder cancer has not shifted much in the past two 
decades. Identifying novel therapies and improving response 
to current therapies may help improve outcomes for patients 
with bladder cancer.
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AUTOPHAGY
Most cancer therapies, such as chemotherapy or radio-
therapy, mediate their effect by promoting apoptotic cell 
death, or programmed cell death. Cancer cells that develop 
the ability to interfere with those pathways subsequently 
develop resistance to primary cancer therapies; often, 
this leads to drug-resistant, more aggressive tumors with 
worse clinical outcomes. Targeting nonapoptotic forms of 
programmed cell death may help overcome this resistance. 
Autophagy is one such pathway.
Autophagy is a constitutively active evolutionary conser-
ved physiologic catabolic process that is maintained at a 
basal rate by cells throughout the body. This means, that 
under normal healthy environmental conditions, it is not 
needed and is suppressed. However, under conditions of cell 
stress, such as hypoxia, radiation or chemotherpy, autophagic 
activity can be increased significantly to ensure sources of 
cellular energy. Activation of the autophagy pathway results 
in sequestration of  intracellular proteins and organelles 
in specialized vacuoles called autophagosomes. These then 
undergo lysosomal-mediated enzymatic degradation to 
recycle organic material to maintain metabolism during 
periods of deprivation [8-10]. The process is fluid and consists 
of  sequential steps (initiation, nucleation, elongation, 
maturation) mediated by a group of  autophagy-related 
genes (ATG genes) [4]. In general, this process helps promote 
survival in a stress response. Cancer cells utilize this 
pathway under conditions of metabolic stress induced by 
different therapies to prolong survival [11,12]. The autophagic 
pathway is shown in Fig. 1 [13]. 
While the role of  autophagy in other malignancies, 
including prostate adenocarcinoma, has been better studied, 
the role of  autophagy in the progression and treatment 
of UC is now being established [13-16]. Indeed, a PubMed 
search for autophagy and bladder cancer resulted in only 70 
articles, with all but one published after 2007. However, it is 
evident based on recent research, that there is a promising 
role for autophagy focused therapies in the field of bladder 
cancer.
UROTHELIAL CANCER PROGRESSION 
AND AUTOPHAGY
While 30% of patients have MIBC at the time of initial 
presentation, there remains a population of patients with 
NMIBC that progress to muscle invasion despite treatment. 
NMIBC has a high recurrence rate and approximately 
10%–30% ultimately progress to MIBC [17]. Unfortunately, 
the biology of progression to muscle-invasion is not clearly 
defined. Recent studies have begun to demonstrate the role 
of autophagy in UC progression. 
Fig. 1. Starvation and growth-factor depri-
vation stimulates cell signaling cascades 
(the key intermediates identified above) 
that ultimately result in the initiation of 
autophagy. The autophagosome matures 
and is trafficked to lysosomes where it 
fuses and creates the autolysosome. The 
autolysosome digests cellular biomass 
and eliminates toxins, facilitating a host 
of favorable nutrient and growth condi-
tions. AMPK, AMP-activated protein kinase; 
mTOR, mechanistic target of rapamycin. 
Adapted from Farrow JM, et al. Nat Rev 
Urol 2014;11:508-16, with permission from 
author C.P.E. [13].
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Ojha et al. [18] collected tumor tissue samples from 30 
patients undergoing TUR of NMIBC, 15 high-grade (HG) 
and 15 low-grade (LG) based on World Health Organization 
histopathologic criteria. They compared this against three 
normal bladder urothelial tissue samples obtained from 
patients undergoing TUR of prostate for benign prostatic 
hyperplasia. Using transmission electron microscopy, they 
demonstrated significantly more autophagic vesicles in 
the HG UC specimens than in the LG UC specimens; both 
contained more autophagic vesicles than the benign tissue. 
Levels of Beclin-1 and Atg7, key proteins associated with 
autophagosome biogenesis, were increased in HG and LG 
UC specimens. Conversion of LC3-I to LC3-II, often used as 
a marker for autophagic induction, was also increased from 
LG UC to HG UC specimens. Both HG and LG UC were 
more susceptible to starvation induced autophagy compared 
to normal urothelial cells. When exposed to autophagy 
inhibitors, such as wortmannin, 3-methyladenine (3MA), and 
chloroquine, under similar starvation conditions, there was 
significantly increased cell death in the HG UC population 
than in the LG UC population. Caspase-9, an initiator 
caspase involved in intrinsic apoptotic pathway, was 
activated in the presence of autophagy inhibitors suggesting 
apoptosis activation as a mechanism of cell death [18].
Sivridis et al. [19] similarly utilized TUR specimens to 
attempt to identify immunohistochemical markers that 
may predict tumor progression. “Stone like” structures 
(SLS) are physical manifestations of undigested cytoplasmic 
constituents due to exhaustion of  lysosomal enzymes 
following autophagic cell death, which are readily identified 
by light microscopy. High numbers of SLS had previously 
been associated with increased aggressiveness and poorer 
prognosis in other epithelial malignancies. In this study, 
250 TUR specimens were analyzed – 70 LG NMIBC, 70 HG 
NMIBC, 70 HG MIBC, and 40 controls. LC3 reactivity and 
SLS concentration was higher in HG NMIBC than in LG 
MIBC, and more importantly, was significantly higher in 
MIBC.
More recent work by Lin et al. [20] demonstrated the 
important of  autophagy in bladder cancer progression 
in known bladder cancer cell lines SV-HUC-1, RT-4, and 
5637. Autophagy inhibition with Baf (bafilomycin) A1 or 
knockdown of Atg-7 resulted in cell death in those same cell 
lines, due to apoptosis induction.
Baspinar et al. [21] took this one step further. Bcl-1 (Beclin 
1) is an important mediator of autophagy. Bcl-1 promotes 
autophagy, and its suppression sensitizes cells to starvation 
induced apoptosis. Eighty-four bladder urothelial tumors 
and 10 normal urothelial specimens from either TUR 
specimens or final cystectomy specimens were examined, 
and they identified a significant inverse correlation between 
Bcl-1 expression and both histologic grade and pT stage 
(p=0.009, r=–0.284; p=0.001, r=–0.361, respectively). The Bcl-
2 family of proteins has oncogenic properties and prevents 
cell death via antiapoptotic pathways; bcl-2 binds to bcl-1 
and inhibits autophagy. As such, they found a significant 
positive correlation between bcl-2 levels and both histologic 
grade and pT stage (p=0.026, r=0.243; p<0.0001, r=0.491, 
respectively) [21]. Shen et al. [22] expanded on this to some 
degree. They focused their efforts on SMYD3, a histone 
methyltransferase, which was associated with poor prognosis 
of patients with prostate and gastric cancer. In their study, 
they noted that patients with higher SMYD3 expression 
had poorer prognosis and worse overall survival than 
patients with lower expression. SMYD3 appears to activate 
autophagy via upregulation of BCL2-associated transcription 
factor 1, which in turn is a strong inducer of autophagy. 
SMYD3 inhibition markedly decreased the activation of 
autophagy in bladder cancer cell lines as well. As such, they 
confirmed the importance of the Bcl-2 as demonstrated by 
Baspinar and colleagues, but also identified a biomarker and 
potential target for therapy [22]. This provides the clinical 
correlation between autophagy and UC progression hinted 
at by the prior studies.
Based on these studies, autophagy clearly plays a role in 
UC progression. As such, it has some important therapeutic 
implications. It may serve as an important target for future 
therapies, and inhibiting its function may help improve 
response to currently approved therapies.
NONMUSCLE INVASIVE BLADDER CAN-
CER
As mentioned previously, NMIBC represents the majority 
(70%–80%) of newly diagnosed bladder cancer cases. While, 
NMIBC itself does not drive bladder cancer mortality, its 
high risk of recurrence and potential for progression make 
it a significant area for improvement in the management 
of  bladder cancer. With 50%–80% of  patients having 
recurrences requiring regular surveillance cystoscopies and 
repeat TURs, the cost burden of NMIBC is also very high. 
Additionally, 10%–30% of patients with NMIBC eventually 
progress to MIBC [23]. 
The current armamentarium utilized by urologists 
for the management of this disease process includes TUR 
of bladder tumors, use of intravesical therapies to reduce 
recurrence and stop progression, and rarely open surgical 
excision (partial cystectomy or radical cystectomy). Due to 
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the complexity of the management of this disease process, 
there are multiple published evidence-based guidelines that 
help guide therapy. 
INTRAVESICAL MITOMYCIN-C
Mitomycin-C is a potent DNA cross-linker chemo-
therapeutic agent. It been utilized intravesically for NMIBC 
and demonstrated reduced risk of  recurrence but not 
necessarily progression of UC. It is recommended as a single 
perioperative dose (or within 24 hours of initial resection) 
for all bladder tumors or those with presumed LG or 
intermediate-grade tumors. In addition, it may be used as an 
adjuvant therapy as weekly instillations in LG tumors [23,24].
As has been suggested by some groups, cancer stem 
cells (CSC) may help drive UC progression. In one study, 
exposure of  primary culture UC cells to mitomycin-C 
increased the percentage of CSCs in the population. The 
CSCs also increased expression of glycolytic genes. Inhibition 
of  autophagy using chloroquine resulted in reduced 
expression of drug resistance genes (MDR1, ABCG2) and also 
sensitized the CSCs to mitomycin-C induced apoptosis. Use 
of chloroquine in combination with mitomycin-C may help 
improve outcomes in LG UC patients [25].
INTRAVESICAL BACILLUS CALMETTE-
GUERIN 
The bacillus Calmette-Guerin (BCG) vaccine is an 
attenuated live bovine tuberculosis bacillus, Mycobacterium 
bovis, utilized internationally as a form of  tuberculosis 
vaccination. In the setting of bladder cancer, it has been 
used as potent immunotherapy. 
All published guidelines recommend use of adjunctive 
intravesical BCG in HG Ta, T1 and carcinoma in situ (CIS) 
tumors, though the specifics of  the administration vary 
to some degree. The European Association of Urology and 
American Urologic Association guidelines advocate the 
longest maintenance schedule of up to 3 years [23,26,27].
With intravesical BCG being a cornerstone of therapy 
for HG NMIBC, and this population being at highest risk 
for progression to MIBC, therapies to help improve BCG 
efficacy carry great potential to affect bladder cancer 
outcomes and reduce need for extirpative surgeries.
While the mechanism of BCG efficacy is not completely 
understood, it is thought to generate a local immune reaction, 
which simultaneously af fects NMIBC. As mentioned 
in Buffen et al. [28], recent literature suggests a process 
called trained immunity, an epigenetic reprogramming 
of monocytes. Specifically, monocytes cells that had been 
previously exposed to BCG were then exposed to Borrelia 
burgdorferi after a six day rest period; cytokine release 
was measured after the second exposure was measured. 
Monocytes previously exposed to BCG had a much higher 
cytokine release after the B. burgdorferi  exposure than 
those pretreated with placebo. They then demonstrated that 
autophagy inhibitors 3MA or wortmannin blocked trained 
immunity; monocytes pretreated with BCG as an initial 
exposure no longer mounted a significant cytokine response 
when exposed to B. burgdorferi in the presence of autophagy 
inhibitors. Specific single nucleotide polymorphisms were 
identified in autophagy-related genes Atg2B and Atg5 
that negatively influenced trained immunity in response 
to BCG, which correlated to a decrease in autophagosome 
production in the monocytes. More importantly, they found 
that in a cohort of 192 NMIBC patients treated with at least 
six instillations of BCG (equivalent to an induction course), 
patients that carry one or two C alleles for the rs3759601 
Atg2B mutation showed increased risk of recurrence and 
progression [28]. 
Improving response to BCG therapy, or even predicting 
those will not respond, can have significant consequences for 
management strategies for NMIBC.
SECOND LINE INTRAVESICAL THERAPIES 
Following BCG failure, the standard of  care remains 
radical cystectomy [26,27]. In terms of alternative therapies, 
valrubicin is the only therapy approved in the United 
States for intravesical salvage therapy, specifically for 
BCG refractory CIS [3,29]. Other intravesical agents have 
been studied for the treatment of NMIBC, and while not 
recommended for primary treatment, the guidelines do allow 
for their consideration in the setting of BCG failure. At this 
time, all utilization is at the discretion of the physician and 
in discussion with the patient.
Despite that, there has been some work with these 
agents and autophagy modulation. 
While interferon alone has been demonstrated to have 
some efficacy as a single agent in patients with BCG 
failure [30], it has more often been studied in combination 
with BCG [31,32]. Benedict et al. [33] had previously report 
that treatment with adenoviral-mediated interferon α (Ad-
IFNα) treatment can overcome interferon resistance. In 
a more recent study, Zhang et al. [34] demonstrate that 
treatment with Ad-IFNα mediates an autophagy response, 
and increased cytotoxicity can be achieved with autophagy 
inhibition using 3MA. 
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In some more recent studies, the use of  intravesical 
gemcitabine in isolation or in combination with mitomycin-C 
has been described for patients with BCG failure, with 
promising results [3,30,35]. In the study by Ojha et al. [25] 
previously mentioned, use of chloroquine as an autophagy 
inhibitor had similar effects on a gemcitabine treated 
cell lines as for mitomycin-C treated cell lines. It reduced 
expression of drug resistance genes (MDR1, ABCG2) and 
also sensitized the CSCs to gemcitabine induced apoptosis. 
Since the combination gemcitabine/mitomycin-C is now 
being described for BCG failure patients, the additional an 
autophagy inhibitor could be synergistic.
Epirubicin, which was found to be inferior in direct 
comparison with BCG for patients with intermediate or 
high risk NMIBC especially in setting of BCG maintenance 
therapy [24], may have a role in combined therapy with 
BCG based on smaller series. One study described a novel 
agent, icaritin, a flavonol glycoside, that had cytotoxic 
efficacy on BT5637 and T24 bladder cancer cells in a time 
and dose dependent manner; more importantly though, it 
was found to work synergistically with epirubicin on those 
same cell lines. Its mechanism was thought to be mediated 
by inhibiting epirubicin mediated autophagy [36]. Similar 
results were seen when assessing pirarubicin, another 
anthracycline described for the treatment of bladder cancer. 
Autophagy inhibition with 3MA or hydroxychloroquine 
significantly increased apoptosis in pirarubicin-treated 
bladder cancer cells, and pirarubicin-induced autophagy was 
mediated via the mammalian target of rapamycin (mTOR)/
p70S6K/4E-BP1 signaling pathway. Knockdown of  Atg3 
generated similar results [37].
PHOTODYNAMIC THERAPY
Photodynamic therapy is an emerging modality 
for treatment of  patients with BCG failure. It involves 
administration of  a photosensitizing agent, such as 
5-aminolevulinic acid, hexaminolevulinate (HAL), or 
radachlorin, with activation of the agent by light at the 
appropriate wavelength. While current studies have mostly 
been smaller and generally underpowered, there is a promise 
for future increased utilization [3]. In an effort to help 
elucidate mechanisms of action of photodynamic therapy 
with HAL, one group utilized a rat xenograft model and 
subsequent electron microscopy to identify changes after 
therapy. They identified significant increased appearance 
of vacuoles and lipofuscin bodies in the cytoplasm following 
treatment, which they attributed to increased autophagy [38]. 
While further work is needed in this area, clearly autophagy 
plays a role in many different treatment modalities of 
bladder cancer.
MUSCLE INVASIVE BLADDER CANCER
Thirty percent of  newly diagnosed bladder cancer 
patients present with MIBC. In additional, as much as 30% 
of patients with NMIBC progress to muscle-invasion. As 
touched on earlier, it is the progression to muscle invasion 
that is the driver behind the mortality of bladder cancer. 
Until approximately 15 years ago, the standard of  care 
remained surgery, specifically radical cystectomy [39].
With the development of platinum-based chemotherapy, 
the first major change in treatment paradigm was intro-
duced [40]. Since its introduction, neoadjuvant chemotherapy 
has been incorporated into all major international guidelines 
based on the strength of its data. The 2 major regimens 
utilized are either MVAC (methotrexate, vinblastine, 
doxorubicin and cisplatin) or GC (gemcitabine and cisplatin); 
recent studies have been utilizing a dose-dense MVAC 
regimen which shortens the duration of treatment. While 
the specific regimen may vary, platinum based neoadjuvant 
chemotherapy is now a standard of care [6,39,41].
Bladder sparing therapies have never been demonstrated 
to be equivalent to cystectomy in this patient population. 
Despite accepted methodological f laws, all currently 
published studies have demonstrated that they have worse 
oncologic outcomes and poorer prognosis. As such, they are 
not recommended for patients eligible for neoadjuvant 
chemotherapy and radical cystectomy. However, in certain 
patients, either due to patient preference or poor candidacy 
for radical cystectomy, bladder sparing options are utilized. 
These options range from external beam radiation therapy 
(EBRT) with or without chemotherapy, partial cystectomy, 
and maximal TUR resections [41].
CHEMOTHERAPY
As can be expected, a significant portion of the research 
associated with autophagy in bladder cancer has focused on 
its potential relationship with chemotherapeutic agents.
Ojha et al. [18] demonstrated that use of  chloroquine, 
the antimalarial drug and a known autophagy inhibitor, 
augmented cisplatin mediated cytotoxicity in T24 cells 
without affecting normal utothelial cells. Mani et al. [4] 
took this one step further. They utilized chemosensitive 
human bladder cancer lines 5637 and RT4, then developed 
chemoresistant cell lines through continuous increasing 
exposure to gemcitabine or cisplatin. They utilized the 
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pan Bcl-2 inhibitor (-)-gossypol to demonstrate that the 
chemotherapy-resistant cell lines utilized autophagy 
to escape apoptotic cell death; indeed, they note that 
overexpression of  Bcl-2 proteins has been associated 
with poor chemotherapeutic response in bladder cancer. 
Administration of 3MA significantly increased (-)-gossypol 
mediated cytotoxicity in those same drug-resistant cell lines. 
Increased LC3 conversion and presence of autophagosomes 
were identified in the chemoresistant strains compared 
to the chemosensitive strains; treatment with (-)-gossypol 
induced even LC3 conversion and autophagosome production 
[4]. 
Sepantronium bromide (YM155), a novel small molecule 
that inhibits survivin, a known pro-apoptotic protein 
overexpressed in urothelial cancer, was the focus of another 
group. While they primarily established that YM155 had 
significant cytotoxic efficacy in the gemcitabine resistant 
bladder cancer lines, they did also demonstrate that 
YM155 mediates significant LC3 conversion independently, 
suggesting its efficacy is in part mediated by autophagy 
activation. Coadministration of  3-methyladenenine 
interestingly reducted YM155 mediated cytotoxicity, which 
the authors contributed to the reduced autophagy mediated 
cell death due to autophagy inhibition by 3MA. Regardless, 
this is a promising agent under clinical trial [42].
Li et al. [43] identified a fungal immunomodulatory 
protein, ganoderma tsugae (FIP-gts), that possesses antitumor 
activity against solid tumors and inhibits telomerase activity. 
When utilized to treat UC cell lines, FIP-gts activated LC-3 II 
conversion, and interestingly, FIP-gts and Baf-A1 combined 
treatment was found to lead to enhancement of apoptosis 
along with inhibition of autophagy in chemosensitive and 
chemoresistant UC cells. They also demonstrated in an 
earlier study that the dual phosphatidylinositol 3-kinase 
(PI3K) and mTOR inhibitor NVP-BEZ235 inhibits UC 
cell growth by activating autophagic flux; it increased 
production of acidic vesicular organelle development but 
did not increase LC3 conversion. Of note, administration 
of  chloraquine counteracted the effect of  NVP-BEZ235, 
demonstrating that the anticancer efficacy of NVP-BEZ235 
is due to autophagic flux and cotreatment with chloroquine 
counteracts the cytotoxic effect [44]. This reminds us that 
autophagy is an important consideration for all future novel 
therapeutic agents in development as well as those currently 
approved.
MicroRNAs (miRNAs) have been gaining recognition in 
their role as regulators of proliferation, migration, invasion 
and apoptosis in cancer cells. Previously, micro-RNA-222 
(miR-222) up-regulation had been noted to be associated 
with a poor prognosis in bladder cancer [45]. Overexpression 
of  miR-222 signif icantly inhibited cisplatin mediated 
cytotoxicity in T24 and 5637 UC cell lines. miR-222 modulates 
the PPP2R2A/Akt/mTOR pathway in UC cells, and mTOR 
is a known regulator of autophagy. miR-222 overexpression 
dramatically reduced cisplatin-mediated autophagy in both 
UC cell lines, demonstrated by the decreased LC3-II levels, 
thereby indicating that miR-222 might block cisplatin-
induced autophagy in bladder cancer cells. As such, miR-222 
may present a viable future target for therapy and help re-
sensitive cells to cisplatin treatment [46].
The mTOR pathway is a regulator of the autophagic 
pathway. Pinto-Leite et al. [47] utilized this fact to assess 
the efficacy of  temsirolimus, a known mTOR inhibitor 
used for the treatment of other solid tumors, in conjunction 
with gemcitabine and cisplatin to 5637, T24, and HT1376 
bladder cancer cell lines. Temsirolimus, in isolation, caused 
mild reduction in proliferation in a three cell lines, but 
in combination with gemcitabine or cisplatin, the effect 
was much more pronounced. Though the increase in 
autophagic cells was mainly pronounced in the temsirolimus 
and cisplatin combination arm, there was a suggestion 
of  autophagy induction and contribution to improved 
cytotoxicity [47].
These studies demonstrate the further research into the 
autophagy process can not only improve response to current 
therapies, but they can provide new targets for future 
therapies and potentially find new indications for previously 
known agents.
RADIOTHERAPY
Although utilized mainly in bladder sparing regimens, 
and often in conjunction with chemotherapy, EBRT does 
have has a role in the management of  MIBC [41,48]. A 
method to better select patients who will respond to EBRT 
may help change guidelines for MIBC management. One 
group looked specifically at HMGB1 (High Mobility Group 
Box protein 1) as a potential predictive marker for EBRT 
response in MIBC. They identified that higher levels of 
HMGB1 correlated with radiotherapy resistance. Indeed, 
with HMGB1 knockdown, >1.5-fold sensitization to radiation 
therapy was achieved, and autophagy was inhibited more 
than 3 folds (as measured by LC3 conversion). HMGB1 
knockdown tumors in their mouse xenograft model showed 
a significantly better response to radiation therapy and 
decreased autophagy as compared to controls [49]. This 
potentially can be a very promising predictive marker and 
even potential target for patients undergoing EBRT. 
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CONCLUSIONS
While the management and morbidity of bladder cancer 
has remained relatively stagnant for the past few decades 
without any significant improvement in outcomes, there 
has been an increasing effort to identify new methods of 
treatment. Autophagy, which has been demonstrated to 
have an important role in treatment resistance in other 
malignancies, is gaining more recognition for its role in 
bladder cancer. At all stages and for all modalities of 
bladder cancer treatment, autophagy has been demonstrated 
to contribute to treatment resistance. Targeting autophagy 
may help augment current treatments and develop novel 
therapies.
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